Overview on sodium glucose transport inhibitors as a therapeutic tool against diabetes mellitus

Global Journal of Pharmacology

Volumn 6, Issue 2, 2012, Pages 86-93

  Singhal, Manmohan ^a   Rasania, Shailee ^a   Gaur, Amit ^a   Vishnu, V R Manchireddy ^a   Raju, S Vijaya Rama ^a   Upadhyay, Yozana ^a  

^a JAIPUR NATIONAL UNIVERSITY   (India)

Author keywords

Dapagliflozin; Diabetes; Glucosuria; Phlorizin; Sodium glucose transport (SGLT)

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; GLUCOSE; GLUCOSE TRANSPORTER; METFORMIN; PHLORIZIN; PLACEBO; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE TRANSPORT INHIBITOR; UNCLASSIFIED DRUG;

CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; GENE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOLECULAR PATHOLOGY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SINGLE DRUG DOSE; SLC5A1 GENE; SLC5A2 GENE; SORE THROAT; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84865551652     PISSN: 19920075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Tian, H.L, L. S. Wei, Z.X. Xu, R. T. Zhao, D.L. Jin, J.S. Gao, 2010. Correlations between blood glucose level and diabetes signs in streptozotocin induced diabetic mice. Global J Pharmacol., 4: 111-116.
2. Arora, S., S.K. Ojha, D. Vohora, 2009. Characterization of streptozotocin induced Diabetes mellitus in swiss albino mice. Global J. Pharmacol., 3: 81-84.
3. Marjani, A. and A. Shirafkan, 2011. The metabolic syndrome in type 2 diabetic patients in Gorgan: According to NCEP ATP III and IDF definitions. Advan. Biol. Res., 5: 200-205.
4. Ibrahim, M.Y., A.M. Abdelatif, 2011. Effects of alloxan-induced diabetes mellitus on blood metabolites and serum minerals and hormones in rabbits (lepus cuniculus) in relation to starch supplementation and season. Advan. Biol. Res., 5: 45-58.
5. Hossien, B.M. and A.A. Mohammad, 2008. Effect of Education on Improvement of Quality of Life by SF-20 in Type 2 Diabetic Patients. Middle-East J. Sci. Res., 3: 67-72.
6. Khushk, I., M.U. Dahot, S.A. Baloach and M.A. Bhutt, 2010. The evaluation of soybean extracts in alloxan induced diabetic rabbits. World Appl. Sci. J., 8: 22-25.
7. Udoh, B.E., B.C. Ezeokpo, K.K. Agwu and O.C. Okpal, 2010. Effects of Type Two Diabetes Mellitus on the Plantar Aponeurosis of Nigerians. World J. Med. Sci., 5: 81-84.
8. Kanai, Y., W.S. Lee, G. You, D. Brown and M.A. Hediger, 1994. The human kidney low affinity Na+/glucose cotransporter SGLT2, Delineation of the major renal re-absorptive mechanism for D-glucose. J. Clin Invest., 93: 397-404.
9. Wright, E.M., B.A. Hirayama and D.F. Loo, 2007. Active sugar transport in health and disease. J. Intern Med., 261: 32-43.
10. Wright, E.M., 2001. Renal Na(+)-glucose cotransporters. Am. J. Physiol. Renal. Physiol., 280: 10-18.
11. Chen, J., J. Feder, I. Neuhaus and J.M. Whaley, 2008. Tissue expression profiling of the sodium-glucose co-transporter (SGLT) family: implication for targeting SGLT2 in type 2 diabetes patients. Diabetes, 57: 2493.
12. Jabbour, S.A. and B.J. Goldstein, 2008. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin Pract., 62: 1279-84.
13. Uldry, M. and B. Thorens, 2004. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch., 447: 480-489.
14. Wood, I.S. and P. Trayhurn, 2003. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br. J. Nutr., 89: 3-9.
15. Wright, E.M. and E. Turk, 2004. The sodium/glucose co-transport family SLC5. Pflugers Arch, 447: 510-518.
16. Wells, R.G., A.M. Pajor, Y. Kanai, E. Turk, E.M. Wright and M.A. Hediger, 1992. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am. J. Physiol., 263: F459-F465.
17. Zhou, L., E.V. Cryan, M.R. D'Andrea, S. Belkowski, B.R. Conway and K.T. Demarest, 2003. Human. cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J. Cell Biochem., 90: 339-346.
18. Li, H., Y. Gu, Y. Zhang, M.J. Lucas and Y. Wang, 2004. High glucose levels down-regulate glucose transporter expression that correlates with increased oxidative stress in placental trophoblast cells in vitro. J. Soc. Gynecol Invest., 11: 75-81.
19. Turk, E., M.G. Martin and E.M. Wright, 1994. Structure of the human Na+/glucose cotransporter gene SGLT1. J Biol Chem., 269: 15204-15209.
20. Martin, M.G., E. Turk, M.P. Lostao, C. Kerner and E.M. Wright, 1996. Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet., 12: 216-220.
21. Vanden, L.P.H., K. Assink, M. Willemsen and L. Monnens, 2002. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet., 111: 544-547.
22. Santer, R., M. Kinner, C.L. Lassen, R. Schneppenheim, et al., 2003. Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria. J. Am. Soc. Nephrol., 14: 2873-2882.
23. Elsas, L.J. and L.E. Rosenberg, 1969. Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine. J Clin Invest., 48: 1845-1854.
24. Elsas, L.J., D. Busse and L.E. Rosenberg, 1971. Autosomal recessive inheritance of renal glycosuria. Metabolism, 20: 968-975.
25. Oemar, B.S., D.J. Byrd and J. Brodehl, 1987. Complete absence of tubular glucose reabsorption. A new type of renal glucosuria (type-0). Clin Nephrol., 27: 156-160.
26. Calado, J., Y. Sznajer, D. Metzger, A. Rita, et al., 2008. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant, 23: 3874-3879.
27. Ganong, W.F., 2005. Formation and excretion of urine. Rev. Med. Physiol., 22: 699-734.
28. Zhai, X.Y., H. Birn, K.B. Jensen, J.S. Thomsen, A. Andreasen and E.I. Christense, 2003. Digital three- dimensional reconstruction and ultrastructure of the mouse proximal tubule. J. Am. Soc. Nephrol., 14: 611-619.
29. Turner, R.J. and A. Moran, 1982. Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am. J. Physiol., 242: F406-F414.
30. Pajor, A.M., B.A. Hirayama and E.M. Wright, 1992. Molecular evidence for two renal Na+/glucose cotransporters. Biochim Biophys Acta, 1106: 216-220.
31. Freitas, H.S., G.F. Anhe, K.F. Melo, M.M. Okamoto, M. Oliveira-Souza, S. Bordin and U.F. Machado, 2008. Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1" expression and activity. Endocrinol., 149: 717-724.
32. Rahmoune, H., P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong and J. Brown, 2005. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin- dependent diabetes. Diabetes, 54: 3427-3434.
33. Kamran, M., R.G. Peterson and J.H. Dominguez, 1997. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J. Am. Soc. Nephrol., 8: 943-948.
34. Dominguez, J.H., K. Camp, L. Maianu, H. Feister and W.T. Garvey, 1994. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am. J. Physiol., 266: F283-F290.
35. Chin, E., A.M. Zamah, D. Landau, H. Gronbcek, A. Flyvbjerg, D. LeRoith and C.A. Bondy, 1997. Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney. Endocrinol., 138: 1267-1275.
36. Oku, A., K. Ueta, K. Arakawa, T. Ishihara, et al., 1999. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes, 48: 1794-1800.
37. Bautista, R., R. Manning, F. Martinez, C. Avila- Casado Mdel, V. Soto, A. Medina and B. Escalante, 2004. Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension. Am. J. Physiol. Renal. Physiol., 286: F127-F133.
38. Ehrenkranz, J.R., N.G. Lewis, C.R. Kahn and J. Roth, 2005. Phlorizin: a review. Diabetes Metab Res. Rev., 21: 31-38.
39. Defronzo, R.A., M. Goldberg and Z. Agus, 1975. Effects of phlorizin and insulin on tubular phosphate reabsorption. Evidence for 2 transport pathways. Kidney Int., 8: 470-472.
40. Panayotova-Heiermann, M., D.D. Loo and E.M. Wright, 1995. Kinetics of steady-state currents and charge movements associated with the rat Na+/glucose cotransporter. J. Biol. Chem., 270: 27099-27105.
41. Tsujihara, K., M. Hongu, K. Saito, M. Inamasu, K. Arakawa, A. Oku and M. Matsumoto, 1996.Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem. Pharm. Bull, 44: 1174-1180.
42. Shi, Z.Q., K.S. Rastogi, M. Lekas, S. Efendic, D.J. Drucker and M. Vranic, 1996. Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats. Endocrinol., 137: 3193-3199.
43. Rossetti, L., D. Smith, G.I. hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin Invest., 79: 1510-1515.
44. Rossetti, L., G.I. Shulman, W. Zawalich and R.A. DeFronzo, 1987. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J. Clin Invest., 80: 1037-1044.
45. Kahn, B.B., G.I. Shulman, R.A. DeFronzo, S.W. Cushman and L. Rossetti, 1991. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J. Clin Invest., 87: 561-570.
46. Katsuno, K., Y. Fujimori, Y. Takemura, M. Hiratochi, F. Itoh, Y. Komatsu, H. Fujikura and M. Isaji, 2007. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther., 320: 323-330.
47. Ueta, K., T. Ishihara, Y. Matsumoto, A. Oku, M. Nawano, T. Fujita, A. Saito and K. Arakawa, 2005. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci., 76: 2655-2668.
48. Meng, W., B.A. Ellsworth, A.A. Nirschl, et al., 2008. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 51: 1145-1149.
49. Fujimori, Y., K. Katsuno, I. Nakashima, Y. Ishikawa- Takemura, H. Fujikura and M. Isaji, 2008. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther., 327: 268-276.
50. Komoroski, B., N. Vachharajani, D. Boulton, D. Kornhauser, M. Geraldes, L. Li and M. Pfister, 2009. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol. Ther., 85: 520-526.
51. Komoroski, B., E. Brenner and L. Li, 2007. Dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, inhibits glucose resorption and reduces fasting glucose in patients with type 2 diabetes mellitus. Diabetologia, 50: S315.
52. Katsuno, K., Y. Fujimori and Y. Takemura, 2007. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther., 320: 323-330.
53. Hussey, E.K., R.L. Dobbins and R.R. Stolz, 2007. A double-blind randomized repeat dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy overweight and obese subjects. Diabetes, 56: 491.
54. Fujimori Y., K. Katsuno, I. Nakashima, Y. Ishikawa- Takemura, H. Fujikura and M. Isaji, 2008. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther., 327: 268-276.
55. Hussey, E.K., R.L. O'Connor-Semmes, W. Tao, J.L. Poo and R.L. Dobbins, 2009. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate (SGLT2 inhibitor) and metformin when co-administered in type 2 diabetes mellitus patients. Proc of the 69 Scientific Session of the American Diabetes Association; 5-9: New Orleans, LA (Abstract 582-P).
56. Kapur, A.R., E. Hussey, R.L. Dobbins, W. Tao, M. Hompesch and D.J. Nunez, 2009. First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus. Proc of the 69th Scientific Session of the American Diabetes Association; 5-9: New Orleans, LA (Abstract 509-P).
57. Calado, J., J. Loeffler and O. Sakallioglu et al., 2006. Familial renal glucosuria: S LC5A2 mutation analysis and evidence of salt-wasting. Kidney Int., 69: 852-855.
58. Isaji, M., 2007. Sodium-glucose cotransporter inhibitors for diabetes. Curr. Opin Investig Drugs, 8: 285-292.